ID.1
Item
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
boolean
ID.2
Item
progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
boolean
ID.3
Item
patients scheduled for treatment with everolimus.
boolean
ID.4
Item
patients with at least one measurable lesion at baseline.
boolean
ID.5
Item
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
boolean
ID.6
Item
patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
boolean
ID.7
Item
patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
boolean
ID.8
Item
patients unwilling or unable to comply with the protocol.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean